



Altimune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

January 2, 2024 at 7:30 AM EST

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease¹ will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH². Details for the presentation are as follows:

Title:	Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (<i>abstract #51</i>)
Authors:	Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne
Date:	Saturday, January 6, 2024

A copy of the abstract will be accessible on the [Events](#) section of the Altimune website.

¹previously termed Non-Alcoholic Fatty Liver Disease

² previously termed NASH

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and MASH, formerly known as NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Investor Contact:

Rich Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

Media Contact:

Danielle Cantey
Evoke Canale
Phone: 619-826-4657
danielle.cantey@evokegroup.com



altimmune

Source: Altimune, Inc